Eva Rohde

TL;DR: It is demonstrated that unmanipulated BM can be used to efficiently initiate MSC cultures without the need for cell separation and can build the basis for standardized manufacturing of MSC-based therapeutics under animal serum-free conditions for dose-escalated cellular therapy and tissue engineering.

TL;DR: Recognizing CFU‐EC formation as the result of a functional cross between T cells and monocytes shifts expectations of vascular regenerative medicine, and supports the move from a view of circulating EPC toward models that include a role for immune cells in vascular regeneration.

TL;DR: It is demonstrated for the first time that human MSCs can be obtained and propagated to a clinical quantity from UCB in a completely bovine serum-free system and functional data indicate the applicability of clinical-grade UCB M SCs propagated with human platelet lysate-conditioned medium for hematopoiesis support, immune regulation and vascular regeneration.

TL;DR: A medium formulation based on pooled human platelet lysate (pHPL), free from animal-derived xenogenic additives and depleted of EVs is developed, appropriate for purification of exclusively human MSC-derived EVs.

TL;DR: A new two‐step procedure has been devised to propagate more than 1 × 108 MSCs from small marrow volumes within fewer than 4 weeks.